Literature DB >> 434096

Long term follow-up study of a trachoma vaccine trial in villages of Northern India.

C Clements, S P Dhir, J T Grayston, S P Wang.   

Abstract

A field trial of two high titer bivalent trachoma vaccines was done in a rural area of Northern India in children under the age of 6 years. Three months later 310 of the original 451 children in the study received a booster vaccination of either of the two vaccines or a placebo. Both the sucrose gradient purified and the Genetron purified vaccine protected against trachoma infection for one year. Significant protection for two years was found only with the gradient vaccine. A 12-year follow-up study located and examined 201 subjects that had received booster vaccine. It was found that 31, 27, and 28% of the individuals in each of the three groups (two vaccine and placebo) had evidence of mostly minimally active trachoma. Additionally, from 6 to 10% of the subjects in each group had signs of mild to moderate potentially blinding sequelae. The results showed no protection by either vaccine, and there was no evidence of adverse effects from the vaccines.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434096     DOI: 10.1016/0002-9394(79)90076-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Authors:  Chunxue Lu; Hao Zeng; Zhihong Li; Lei Lei; I-Tien Yeh; Yimou Wu; Guangming Zhong
Journal:  Vaccine       Date:  2011-11-10       Impact factor: 3.641

2.  A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct.

Authors:  Jose Rey-Ladino; Kasra M Koochesfahani; Michelle L Zaharik; Caixia Shen; Robert C Brunham
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 3.  Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.

Authors:  Rajnish Sahu; Richa Verma; Saurabh Dixit; Joseph U Igietseme; Carolyn M Black; Skyla Duncan; Shree R Singh; Vida A Dennis
Journal:  Expert Rev Vaccines       Date:  2018-02-06       Impact factor: 5.217

4.  Genome-wide identification of Chlamydia trachomatis antigens associated with trachomatous trichiasis.

Authors:  Chunxue Lu; Martin J Holland; Siqi Gong; Bo Peng; Robin L Bailey; David W Mabey; Yimou Wu; Guangming Zhong
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-14       Impact factor: 4.799

Review 5.  Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis.

Authors:  Victor H Hu; Martin J Holland; Matthew J Burton
Journal:  PLoS Negl Trop Dis       Date:  2013-02-14

6.  Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine.

Authors:  Shakyra Richardson; Fnu Medhavi; Tayhlor Tanner; Stephanie Lundy; Yusuf Omosun; Joseph U Igietseme; Darin Carroll; Francis O Eko
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.